Skip to content

Dexmedetomidine, Magnesium Sulphate and Lidocaine for Cough Suppression After General Anesthesia

Comparative Study Between Efficacy of Dexmedetomidine, Magnesium Sulphate and Lidocaine for Cough Suppression During General Anesthetic Emergence

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06979141
Acronym
MgSO4/DEX
Enrollment
300
Registered
2025-05-18
Start date
2025-06-02
Completion date
2026-08-01
Last updated
2025-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cough

Brief summary

The aim of this prospective randomized controlled double-blinded study is to compare the efficacy of dexmedetomidine, MgSO4 and lidocaine for cough suppression during general anesthetic emergence as regard number and severity.

Interventions

DRUGDexmedetomidine

Patients will receive 0.5 μg/kg dexmedetomidine in 10ml normal saline 10 min before the end of surgery.

DRUGMagnesium sulfate

Patients will receive 30 mg/kg IV magnesium sulfate 50% 10 min before the end of surgery.

DRUGLidocaine

Patients will receive lidocaine 1.5 mg/kg lidocaine 10 min before the end of surgery.

DRUGnormal saline

Patients will receive 10 ml normal saline 10 min before the end of surgery.

Sponsors

Al-Azhar University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
21 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* Aged 21-60 years. * Both genders. * Body mass index \< 30 kg/ m2 * American Society of Anesthesiology (ASA) physical status I-II. * Mallampati score class I or II. * Patients undergoing surgery under general anesthesia.

Exclusion criteria

* Known allergy to study drugs. * History of psychiatric illness. * Patients with major organ diseases. * Pre-existing neurological deficits. * Body mass index \>30 kg/m2. * Active airway infection or history of tracheal and laryngeal surgery. * Lower esophageal sphincter incompetence (and reflux). * Increased intracranial and intraocular pressure. * Use of cough-inducing medications * Pregnant, and lactating women.

Design outcomes

Primary

MeasureTime frameDescription
Cough suppression as regard number and severity.at 0 and 10,20,30,40 minutes after endotracheal extubation.Coughing severity will be classified using the 3 point scale described by Minogue et al.: 1 = mild, single cough, 2 = moderate (lasting for \<5 seconds) cough, and severe (lasting for \>5 seconds) cough.

Secondary

MeasureTime frameDescription
Intraoperative heart rate (HR).at 15-minutes interval.Changes in Intraoperative heart rate. change in heart rate per minute (HR/minute) will be all measured from the patient's arrival at the operating room to the end of surgery.
Intraoperative mean arterial blood pressure (MAP).at 15-minutes interval.Changes in Intraoperative mean arterial blood pressure (MAP). change in mean arterial blood pressure (MAP) in mmHg will be all measured from the patient's arrival at the operating room to the end of surgery.
Intraoperative arterial oxygen saturation (Spo2).at 15-minutes interval.Changes in Intraoperative arterial oxygen saturation (Spo2%). change in arterial oxygen saturation (Spo2%). be all measured from the patient's arrival at the operating room to the end of surgery.
Sedation score.at 0,10,20,30, and 40 minutes after tracheal extubation.Sedation score will be recorded using the Ramsay sedation score (Ramsay et al., 1974).

Countries

Egypt

Contacts

Primary ContactMedhat H Allam, lecturer.MD
Medhathelaly@gmail.com1003012989
Backup ContactOsama H Ahmed, Professor.MD
DOCTOR_OSAMA_HELAL@hotmail.com1223460571

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026